In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

One-hour rule-out and rule-in of acute myocardial infarction using a novel ultra-sensitive cardiac troponin I assay

Session Poster Session 7

Speaker Raphael Twerenbold

Event : ESC Congress 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Biomarkers
  • Session type : Poster Session

Authors : R Twerenbold (Basel,CH), J Boeddinghaus (Basel,CH), T Nestelberger (Basel,CH), M Rubini Gimenez (Basel,CH), C Puelacher (Basel,CH), P Badertscher (Basel,CH), J Du Fay De Lavallaz (Basel,CH), D Wussler (Basel,CH), N Kozhuharov (Basel,CH), O Miro (Barcelona,ES), FJ Martin-Sanchez (Madrid,ES), B Morawiec (Katowice,PL), D Keller (Zurich,CH), T Reichlin (Basel,CH), C Mueller (Basel,CH)

R. Twerenbold1 , J. Boeddinghaus1 , T. Nestelberger1 , M. Rubini Gimenez1 , C. Puelacher1 , P. Badertscher1 , J. Du Fay De Lavallaz1 , D. Wussler1 , N. Kozhuharov1 , O. Miro2 , F.J. Martin-Sanchez3 , B. Morawiec4 , D. Keller5 , T. Reichlin1 , C. Mueller1 , 1University Hospital Basel - Basel - Switzerland , 2Hospital Clinic de Barcelona - Barcelona - Spain , 3Hospital Clinic San Carlos - Madrid - Spain , 4Medical University of Silesia, Cardiology department - Katowice - Poland , 5University Hospital Zurich - Zurich - Switzerland ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 1368-1369

Background: The European Society of Cardiology suggests the use of a 0/1h-algorithm for rapid rule-out and rule-in of acute myocardial infarction (AMI) based on high-sensitivity cardiac troponin (hs-cTn).

Purpose: We aimed to derive and validate a new 0/1h-algorithm for a novel ultra-sensitive cTnI assay, providing 10x higher analytical performance compared to hs-cTnT/I.

Methods: In a prospective international multicentre diagnostic study enrolling patients presenting with suspected AMI to the ED, us-cTnI was determined at baseline and after one hour using Singulex Clarity us-cTnI. Patients presenting with STEMI were excluded. The final diagnosis was centrally adjudicated by two independent cardiologists using all available data including coronary angiography, echocardiography, follow-up data, and serial measurements of hs-cTnT (but not hs-cTnI). The us-cTnI 0/1h-algorithm, incorporating measurements performed at baseline and absolute changes within 1 hour, was derived in a randomly selected sample of 987 patients (derivation sample) using classification and regression tree (CART) analysis, and then validated in the remaining 987 patients (validation sample).

Results: AMI was the final diagnosis in 17% of the 1974 recruited patients. After applying the us-cTnI 0/1h-algorithm developed in the derivation cohort to the validation cohort, 56% of patients could be classified as “rule-out”, 16% as “rule-in”, and 29% as “observe” (Figure 1). Direct rule-out based on the baseline us-cTnI-concentration was feasible in 23%. In the validation cohort, the derived rule-out strategy resulted in a negative predictive value for AMI of 99.6% (95% confidence interval (CI), 98.6–99.9%) and a sensitivity of 98.8% (95% CI, 95.9–99.9%) while the derived rule-in strategy resulted in a positive predictive value for AMI of 79.7% (95% CI, 73.3–84.9%) and a specificity of 96.2% (95% CI, 94.6–97.4%).

Conclusion: Using a simple algorithm incorporating baseline us-cTnI concentrations and their absolute changes within the first hour, measured with a novel us-cTnI assay, allows very safe rule-out as well as accurate rule-in of AMI in more than two patients out of three presenting with suspected AMI.

Figure 1

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are